Pharmacy School

AstraZeneca and Emergent Enter COVID-19 Vax Agreement

Emergent to provide development and manufacturing services and secure large-scale manufacturing capacity through 2020 for AstraZeneca’s COVID-19 vax candidate.

Emergent BioSolutions has inked a manufacturing agreement with AstraZeneca. The CDMO said it will deploy its molecule-to-market contract development and manufacturing services to support the manufacturing of AstraZeneca’s vaccine candidate for COVID-19, AZD1222, a viral vector-based, weakened version of adenovirus containing the genetic material of SARS-CoV-2 spike protein, developed by Oxford University’s Jenner institute working with the Oxford Vaccine Group.

Read more…